Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.
Numinus Wellness Inc. (NUMIF) is a mental health care company dedicated to advancing traditional and innovative behavioral health treatments through safe, evidence-based psychedelic-assisted therapies. They aim to heal rather than manage symptoms of depression, anxiety, trauma, pain, and substance use. By leading the integration of psychedelic-assisted therapies into mainstream clinical practice, Numinus is pioneering a healthier society. Numinus helps individuals heal and be well by providing innovative mental health care and access to safe, evidence-based therapies.
Rhea-AI Summary
Numinus Wellness Inc. congratulates Mind Medicine on positive data from Phase 2b clinical trial of MM120 for GAD, showing significant improvement in anxiety treatment. FDA designates MM120 as a breakthrough therapy for GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. announced its Q1 2024 financial results, reporting a gross profit of $2.1 million, a 18.8% increase over Q4 2023, and a revenue decline of 3.0%. The company reduced operating expenditures by 19.9% and achieved a cash position of $4.7 million. Numinus managed 22 clinical trials and provided 19,961 client appointments in its wellness clinics. The company's focus on cost containment efforts resulted in a monthly cash burn rate of less than $1 million. Revenue declined due to a contraction in scheduled appointments at wellness clinics, but gross margin increased by 660 basis points. The company continues to focus on profitability and sustainability, with a total cash balance of $4.7 million and working capital of $4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) to release Q1 2024 financial results on January 15, 2024, with a focus on psychedelic-assisted therapies. Investors and analysts can participate in the conference call and webcast to review the Company's performance and recent initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.95%
Tags
News
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) has announced that its research site, Cedar Clinical Research (CCR), has been selected as one of multiple sites for Beckley Psytech's Phase 2b clinical trial for Treatment Resistant Depression (TRD). The study aims to evaluate the efficacy and safety of Beckley Psytech's proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) as a potential therapy for TRD. Numinus and CCR's collaboration with Beckley Psytech reflects a unified drive for innovation in psychedelic-assisted therapies, showcasing their dedication to advancing mental health research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.86%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) congratulates MAPS PBC for submitting an NDA to the FDA for MDMA-assisted therapy for PTSD. Numinus expands its Practitioner Training Program and receives a notification from OTC Markets Inc. regarding its OTCQX compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) Q4 2023 Highlights: Revenues grew 46.8% YoY to $6.1M, gross profit increased 37.4%, cash position at $8.6M, and fiscal 2023 revenue of $23.2M, a 256.9% increase over F2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) to Release Financial Results for Q4 and Year-End 2023, Announces Conference Call and Webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Numinus introduces innovative psychedelic program for mental distress associated with chronic and serious illness
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. establishes an at-the-market equity offering program, allowing the company to issue and sell up to C$10,000,000 of common shares. The program provides flexibility for future financing and general corporate purposes. No shares have been distributed yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
Rhea-AI Summary
Numinus congratulates MAPS on its phase 3 study results published in Nature Medicine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
FAQ
What is the current stock price of NUMINUS WELLNESS (NUMIF)?
The current stock price of NUMINUS WELLNESS (NUMIF) is $0.0321 as of November 22, 2024.
What is the market cap of NUMINUS WELLNESS (NUMIF)?
The market cap of NUMINUS WELLNESS (NUMIF) is approximately 12.7M.
What is Numinus Wellness Inc. focused on?
Numinus Wellness Inc. is dedicated to advancing mental health care through traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies.
What is Numinus Wellness Inc.'s mission?
Numinus Wellness Inc. aims to heal rather than manage symptoms for various mental health conditions such as depression, anxiety, trauma, pain, and substance use by integrating psychedelic-assisted therapies into mainstream clinical practice.
How does Numinus Wellness Inc. contribute to mental health care?
Numinus Wellness Inc. provides innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies, leading to healing and well-being for individuals.
What sets Numinus Wellness Inc. apart from other mental health care providers?
Numinus Wellness Inc. distinguishes itself by promoting healing through psychedelic-assisted therapies rather than symptom management, pioneering a healthier society.
What is the goal of Numinus Wellness Inc. in the mental health care space?
Numinus Wellness Inc. aims to integrate psychedelic-assisted therapies into mainstream clinical practice, transforming mental health care and building a foundation for a healthier society.
NUMINUS WELLNESS INC
OTC:NUMIF
NUMIF Rankings
NUMIF Stock Data
12.74M
309.90M
3.85%
2.67%
Medical Care Facilities
Healthcare
United States of America
Vancouver